The FDA's preliminary evaluation of GLP-1 RAs found no evidence that the medications cause suicidal drugs or actions but cautions that a small risk cannot yet be ruled out.
The FDA's preliminary evaluation of GLP-1 RAs found no evidence that the medications cause suicidal drugs or actions but cautions that a small risk cannot yet be ruled out.
The FDA's preliminary evaluation...